Cancer du sein: Prédictivité de la réponse à la chimiothérapie néoadjuvante

Roman Rouzier; Charles Coutant; Roberto Incitti; René Natowicz; Georges Chahine; Serge Uzan; David Atallah

Cancer du sein: Prédictivité de la réponse à la chimiothérapie néoadjuvante

Translated title of the contribution: Breast cancer: Nomograms to predict pathologic response after preoperative chemotherapy

Roman Rouzier^*, Charles Coutant, Roberto Incitti, René Natowicz, Georges Chahine, Serge Uzan, David Atallah

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

If the benefit of adjuvant chemotherapy may be determined at the level of a population, to determine the real chemosensitivity of a tumor at the individual level is impossible. The concept of neoadjuvant chemotherapy in patients with localized breast cancer is interesting because it helps to know the chemosensitivity of a tumor "in vivo". It is possible to use a single criterion to predict the effectiveness of targeted therapies. The chemotherapy is not a targeted therapy, and to determine a biological predictive marker of the response has been impossible so far. The development of mathematical models and use of molecular biology may help to predict chemosensitivity. Initial results are promising. The validation of published works is necessary, but applications are numerous.

Translated title of the contribution	Breast cancer: Nomograms to predict pathologic response after preoperative chemotherapy
Original language	French
Pages (from-to)	89-92
Number of pages	4
Journal	Journal Medical Libanais
Volume	57
Issue number	2
State	Published - Apr 2009
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{27119ffda4d040849da7e2c721ddccfa,

title = "Cancer du sein: Pr{\'e}dictivit{\'e} de la r{\'e}ponse {\`a} la chimioth{\'e}rapie n{\'e}oadjuvante",

abstract = "If the benefit of adjuvant chemotherapy may be determined at the level of a population, to determine the real chemosensitivity of a tumor at the individual level is impossible. The concept of neoadjuvant chemotherapy in patients with localized breast cancer is interesting because it helps to know the chemosensitivity of a tumor {"}in vivo{"}. It is possible to use a single criterion to predict the effectiveness of targeted therapies. The chemotherapy is not a targeted therapy, and to determine a biological predictive marker of the response has been impossible so far. The development of mathematical models and use of molecular biology may help to predict chemosensitivity. Initial results are promising. The validation of published works is necessary, but applications are numerous.",

author = "Roman Rouzier and Charles Coutant and Roberto Incitti and Ren{\'e} Natowicz and Georges Chahine and Serge Uzan and David Atallah",

year = "2009",

month = apr,

language = "French",

volume = "57",

pages = "89--92",

journal = "Journal Medical Libanais",

issn = "0023-9852",

publisher = "Lebanese Order of Physicians",

number = "2",

}

TY - JOUR

T1 - Cancer du sein

T2 - Prédictivité de la réponse à la chimiothérapie néoadjuvante

AU - Rouzier, Roman

AU - Coutant, Charles

AU - Incitti, Roberto

AU - Natowicz, René

AU - Chahine, Georges

AU - Uzan, Serge

AU - Atallah, David

PY - 2009/4

Y1 - 2009/4

N2 - If the benefit of adjuvant chemotherapy may be determined at the level of a population, to determine the real chemosensitivity of a tumor at the individual level is impossible. The concept of neoadjuvant chemotherapy in patients with localized breast cancer is interesting because it helps to know the chemosensitivity of a tumor "in vivo". It is possible to use a single criterion to predict the effectiveness of targeted therapies. The chemotherapy is not a targeted therapy, and to determine a biological predictive marker of the response has been impossible so far. The development of mathematical models and use of molecular biology may help to predict chemosensitivity. Initial results are promising. The validation of published works is necessary, but applications are numerous.

AB - If the benefit of adjuvant chemotherapy may be determined at the level of a population, to determine the real chemosensitivity of a tumor at the individual level is impossible. The concept of neoadjuvant chemotherapy in patients with localized breast cancer is interesting because it helps to know the chemosensitivity of a tumor "in vivo". It is possible to use a single criterion to predict the effectiveness of targeted therapies. The chemotherapy is not a targeted therapy, and to determine a biological predictive marker of the response has been impossible so far. The development of mathematical models and use of molecular biology may help to predict chemosensitivity. Initial results are promising. The validation of published works is necessary, but applications are numerous.

UR - http://www.scopus.com/inward/record.url?scp=67749118061&partnerID=8YFLogxK

M3 - Short survey

C2 - 19623884

AN - SCOPUS:67749118061

SN - 0023-9852

VL - 57

SP - 89

EP - 92

JO - Journal Medical Libanais

JF - Journal Medical Libanais

IS - 2

ER -

Cancer du sein: Prédictivité de la réponse à la chimiothérapie néoadjuvante

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this